See more : Tsim Sha Tsui Properties Limited (0247.HK) Income Statement Analysis – Financial Results
Complete financial analysis of America Great Health (AAGH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of America Great Health, a leading company in the Biotechnology industry within the Healthcare sector.
- Esperion Therapeutics, Inc. (0IIM.L) Income Statement Analysis – Financial Results
- Diffusion Engineers Limited (DIFFNKG.NS) Income Statement Analysis – Financial Results
- HFB Financial Corporation (HFBA) Income Statement Analysis – Financial Results
- Fiore Cannabis Ltd. (FIOR.CN) Income Statement Analysis – Financial Results
- SPCG Public Company Limited (SPCG.BK) Income Statement Analysis – Financial Results
America Great Health (AAGH)
About America Great Health
America Great Health operates as a biotechnology company in the United States. It focuses on the research and development of protein and peptide small molecular drugs; and the manufacturing and sale of AI cloud computing-based diagnostic and medical devices, cell therapy, and regenerative medicine and supplements. The company was formerly known as Crown Marketing and changed its name to America Great Health in March 2017. America Great Health was founded in 2013 and is headquartered in Alhambra, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 204.31K | 104.65K | 195.67K | 5.47K | 0.00 | 0.00 | 0.00 | 3.17M | 43.37K | 0.00 | 6.63K | 4.50K | 0.00 |
| Cost of Revenue | 35.72K | 1.59M | 144.32K | 3.37K | 0.00 | 0.00 | 0.00 | 2.96M | 59.31K | 0.00 | 0.00 | 456.00 | 0.00 |
| Gross Profit | 168.59K | -1.48M | 51.35K | 2.11K | 0.00 | 0.00 | 0.00 | 215.51K | -15.94K | 0.00 | 6.63K | 4.04K | 0.00 |
| Gross Profit Ratio | 82.52% | -1,417.90% | 26.24% | 38.45% | 0.00% | 0.00% | 0.00% | 6.79% | -36.76% | 0.00% | 100.00% | 89.87% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 122.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 657.23K | 3.16M | 294.91K | 48.26K | 46.77K | 58.15K | 48.37K | 1.23M | 644.15K | 0.00 | 114.00K | 0.00 | 0.00 |
| Selling & Marketing | 4.00K | 86.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.14M | -644.54K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 661.23K | 3.25M | 294.91K | 48.26K | 46.77K | 58.15K | 48.37K | 1.23M | 644.15K | 605.62K | 114.00K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 73.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.30K | 0.00 | 0.00 | 0.00 | 60.31K | 22.02K |
| Operating Expenses | 661.23K | 3.25M | 294.91K | 48.26K | 46.77K | 58.15K | 48.37K | 1.36M | 644.15K | 605.62K | 114.00K | 60.31K | 22.02K |
| Cost & Expenses | 696.95K | 4.84M | 439.23K | 51.63K | 46.77K | 58.15K | 48.37K | 4.32M | 703.46K | 605.62K | 114.00K | 60.76K | 22.02K |
| Interest Income | 26.00 | 5.00 | 20.04K | 4.97K | 4.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 319.71K | 190.92K | 20.04K | 4.97K | 4.49K | 0.00 | 54.98K | 0.00 | 0.00 | 1.43K | 0.00 | 0.00 | |
| Depreciation & Amortization | 10.35K | 5.91K | 243.56K | 46.15K | 46.77K | 58.15K | 48.37K | 22.82K | 660.09K | 605.62K | 0.00 | 0.00 | 0.00 |
| EBITDA | -447.29K | -4.73M | -249.01K | -46.15K | 0.00 | 0.00 | 0.00 | -1.14M | -660.09K | 0.00 | -107.37K | -56.26K | -22.02K |
| EBITDA Ratio | -218.93% | -4,518.11% | -127.26% | -843.09% | 0.00% | 0.00% | 0.00% | -35.95% | -1,522.01% | 0.00% | -1,620.25% | -1,250.24% | 0.00% |
| Operating Income | -492.64K | -4.73M | -243.56K | -46.15K | -46.77K | -58.15K | -48.37K | -1.14M | -660.09K | -605.62K | -107.37K | -56.26K | -22.02K |
| Operating Income Ratio | -241.13% | -4,523.83% | -124.47% | -843.09% | 0.00% | 0.00% | 0.00% | -35.95% | -1,522.01% | 0.00% | -1,620.25% | -1,250.24% | 0.00% |
| Total Other Income/Expenses | -284.70K | -190.84K | -25.49K | -4.97K | -17.47K | -437.00 | 0.00 | -9.68K | 0.00 | 0.00 | -1.43K | 0.00 | 0.00 |
| Income Before Tax | -777.34K | -4.92M | -269.05K | -51.12K | -64.24K | -58.59K | -48.37K | -1.15M | -660.09K | -605.62K | -108.80K | -56.26K | -22.02K |
| Income Before Tax Ratio | -380.47% | -4,706.19% | -137.50% | -933.80% | 0.00% | 0.00% | 0.00% | -36.26% | -1,522.01% | 0.00% | -1,641.77% | -1,250.24% | 0.00% |
| Income Tax Expense | 0.00 | -58.78K | 20.04K | 800.00 | 800.00 | 800.00 | 918.67K | -9.94K | -15.56K | 0.00 | 0.00 | 56.26K | 22.02K |
| Net Income | -761.42K | -4.87M | -269.05K | -51.92K | -65.04K | -59.39K | -918.67K | -1.14M | -15.56K | -605.62K | -108.80K | -56.26K | -22.02K |
| Net Income Ratio | -372.68% | -4,650.02% | -137.50% | -948.41% | 0.00% | 0.00% | 0.00% | -35.94% | -35.87% | 0.00% | -1,641.77% | -1,250.24% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 21.09B | 21.09B | 20.44B | 20.24B | 20.24B | 20.24B | 20.18B | 20.05B | 19.98B | 19.98B | 190.07M | 43.47M | 42.29M |
| Weighted Avg Shares Out (Dil) | 21.09B | 21.09B | 20.44B | 20.24B | 20.24B | 20.24B | 20.18B | 20.05B | 19.98B | 19.98B | 190.07M | 43.47M | 42.29M |
Source: https://incomestatements.info
Category: Stock Reports